Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB… Read more
Estrella Immunopharma Inc. (ESLA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.074x
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has a cash flow conversion efficiency ratio of 0.074x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-727.33K) by net assets ($-9.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Estrella Immunopharma Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Estrella Immunopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Estrella Immunopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Estrella Immunopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JOY SPREADER GROUP INC.
F:5YN
|
N/A |
|
Oriental Carbon & Chemicals Limited
NSE:OCCL
|
0.052x |
|
Tander Inversiones SOCIMI SA
MC:YTAN
|
0.016x |
|
AMIGO HLDGS PLC. LS-0025
F:0VG
|
N/A |
|
Kino Indonesia Tbk PT
JK:KINO
|
0.082x |
|
Hydrogene De France SA
PA:HDF
|
-0.075x |
|
Kip Mcgrath Education Centres Ltd
AU:KME
|
0.196x |
|
Cauldron Energy Ltd
AU:CXU
|
-0.606x |
Annual Cash Flow Conversion Efficiency for Estrella Immunopharma Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $143.73K | $-7.64 Million | -53.153x | -1313.63% |
| 2023-12-31 | $4.27 Million | $-16.07 Million | -3.760x | -2446.93% |
| 2022-12-31 | $7.07 Million | $-1.04 Million | -0.148x | -110.65% |
| 2021-12-31 | $-1.04 Million | $-1.44 Million | 1.387x | -- |
| 2020-12-31 | $0.00 | $-670.82K | x | -- |